A prospective split-face double-blind randomized placebo-controlled trial to assess the efficacy of vitamin C and ferulic acid serum postfractional ablative laser for skin rejuvenation

Abstract Background High-dose intravenous vitamin C directly scavenges and decreases the production of harmful reactive oxygen species (ROS) generated during ischemia/reperfusion after a cardiac arrest. The aim of this study is to investigate whether short-term treatment with a supplementary or very high-dose intravenous vitamin C reduces organ failure in post-cardiac arrest patients. Methods This is a double-blind, multi-center, randomized placebo-controlled trial conducted in 7 intensive care units (ICUs) in The Netherlands. A total of 270 patients with cardiac arrest and return of spontaneous circulation will be randomly assigned to three groups of 90 patients (1:1:1 ratio, stratified by site and age). Patients will intravenously receive a placebo, a supplementation dose of 3 g of vitamin C or a pharmacological dose of 10 g of vitamin C per day for 96 h. The primary endpoint is organ failure at 96 h as measured by the Resuscitation-Sequential Organ Failure Assessment (R-SOFA) score at 96 h minus the baseline score (delta R-SOFA). Secondary endpoints are a neurological outcome, mortality, length of ICU and hospital stay, myocardial injury, vasopressor support, lung injury score, ventilator-free days, renal function, ICU-acquired weakness, delirium, oxidative stress parameters, and plasma vitamin C concentrations. Discussion Vitamin C supplementation is safe and preclinical studies have shown beneficial effects of high-dose IV vitamin C in cardiac arrest models. This is the first RCT to assess the clinical effect of intravenous vitamin C on organ dysfunction in critically ill patients after cardiac arrest. Trial registration ClinicalTrials.gov NCT03509662. Registered on April 26, 2018. https://clinicaltrials.gov/ct2/show/NCT03509662European Clinical Trials Database (EudraCT): 2017-004318-25. Registered on June 8, 2018. https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004318-25/NL

Download Full-text

Anti‐aging and brightening effects of a topical treatment containing vitamin C, vitamin E, and raspberry leaf cell culture extract: A split‐face, randomized controlled trial

Journal of Cosmetic Dermatology ◽

10.1111/jocd.13305 ◽

2020 ◽

Vol 19 (3) ◽

pp. 671-676 ◽

Cited By ~ 4

Author(s):

Pattarawan Rattanawiwatpong ◽

Rungsima Wanitphakdeedecha ◽

Akkarach Bumrungpert ◽

Mart Maiprasert

Keyword(s):

Cell Culture ◽

Randomized Controlled Trial ◽

Vitamin E ◽

Vitamin C ◽

Topical Treatment ◽

Controlled Trial ◽

Leaf Cell ◽

Randomized Controlled ◽

Culture Extract ◽

Split Face

Download Full-text

Comparing the efficacy of Myjet‐assisted tranexamic acid and vitamin C in treating melasma: A split‐face controlled trial

Journal of Cosmetic Dermatology ◽

10.1111/jocd.13112 ◽

2019 ◽

Vol 19 (1) ◽

pp. 47-54

Author(s):

Huijuan Zhao ◽

Mengna Li ◽

Xiaofeng Zhang ◽

Li Li ◽

Yan Yan ◽

...

Keyword(s):

Vitamin C ◽

Tranexamic Acid ◽

Controlled Trial ◽

Split Face

Download Full-text

Vitamin C to pregnant smokers persistently improves infant airway function to 12 months of age: a randomised trial

European Respiratory Journal ◽

10.1183/13993003.02208-2019 ◽

2020 ◽

Vol 56 (6) ◽

pp. 1902208 ◽

Cited By ~ 1

Author(s):

Cindy T. McEvoy ◽

Lyndsey E. Shorey-Kendrick ◽

Kristin Milner ◽

Diane Schilling ◽

Christina Tiller ◽

...

Keyword(s):

Vitamin C ◽

Repeated Measures ◽

Controlled Trial ◽

Randomised Trial ◽

Analysis Of Covariance ◽

Secondary Outcome ◽

Double Blind ◽

Smoking Cessation Counselling ◽

Airway Function ◽

Pregnant Smokers

BackgroundVitamin C (500 mg·day−1) supplementation for pregnant smokers has been reported to increase newborn pulmonary function and infant forced expiratory flows (FEFs) at 3 months of age. Its effect on airway function through 12 months of age has not been reported.ObjectiveTo assess whether vitamin C supplementation to pregnant smokers is associated with a sustained increased airway function in their infants through 12 months of age.MethodsThis is a pre-specified secondary outcome of a randomised, double-blind, placebo-controlled trial that randomised 251 pregnant smokers between 13 and 23 weeks of gestation: 125 to 500 mg·day−1 vitamin C and 126 to placebo. Smoking cessation counselling was provided. FEFs performed at 3 and 12 months of age were analysed by repeated-measures analysis of covariance.ResultsFEFs were performed in 222 infants at 3 months and 202 infants at 12 months of age. The infants allocated to vitamin C had significantly increased FEFs over the first year of life compared to those allocated to placebo. The overall increased flows were 40.2 mL·s−1 for at FEF75 (75% of forced vital capacity (FVC)) (adjusted 95% CI for difference 6.6–73.8; p=0.025); 58.3 mL·s−1 for FEF50 (10.9–105.8; p=0.0081); and 55.1 mL·s−1 for FEF25–75 (9.7–100.5; p=0.013).ConclusionsIn offspring of pregnant smokers randomised to vitamin C versus placebo, vitamin C during pregnancy was associated with a small but significantly increased airway function at 3 and 12 months of age, suggesting a potential shift to a higher airway function trajectory curve. Continued follow-up is underway.

Download Full-text

Administration of Vitamin C and Vitamin E in Severe Head Injury: A Randomized Double-blind Controlled Trial

Neurosurgery ◽

10.1227/neu.0b013e3182279a8f ◽

2011 ◽

Vol 58 ◽

pp. 133-137 ◽

Cited By ~ 23

Author(s):

Ali Razmkon ◽

Ahmad Sadidi ◽

Ehsan Sherafat-Kazemzadeh ◽

Ali Mehrafshan ◽

Mohammad Jamali ◽

...

Keyword(s):

Vitamin E ◽

Head Injury ◽

Vitamin C ◽

Severe Head Injury ◽

Controlled Trial ◽

Double Blind

Download Full-text

Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial

Beneficial Microbes ◽

10.3920/bm2020.0185 ◽

2021 ◽

pp. 1-10

Author(s):

I. Garaiova ◽

Z. Paduchová ◽

Z. Nagyová ◽

D. Wang ◽

D.R. Michael ◽

...

Keyword(s):

Vitamin C ◽

Respiratory Tract ◽

Controlled Trial ◽

Bifidobacterium Bifidum ◽

Active Group ◽

Controlled Study ◽

Upper Respiratory Tract ◽

Double Blind ◽

Upper Respiratory ◽

The Impact

In a double-blind, randomised, parallel-group, placebo-controlled study, healthy school children aged 3-10 years received a probiotic based supplement daily for 6 months to assess the impact on the incidence and duration of upper respiratory tract infection (URTI) symptoms. The intervention comprised Lab4 probiotic (Lactobacillus acidophilus CUL21 and CUL60, Bifidobacterium bifidum CUL20 and Bifidobacterium animalis subsp. lactis CUL34) at 12.5 billion cfu/day plus 50 mg vitamin C or a matching placebo. 171 children were included in the analysis (85 in placebo and 86 in active group). Incidence of coughing was 16% (P=0.0300) significantly lower in the children receiving the active intervention compared to the placebo. No significant differences in the incidence rate of other URTI symptoms were observed. There was significantly lower risk of experiencing five different URTI related symptoms in one day favouring the active group (Risk ratio: 0.31, 95% confidence interval: 0.12, 0.81, P=0.0163). Absenteeism from school and the use of antibiotics was also significantly reduced for those in the active group (-16%, P=0.0060 and -27%, P=0.0203, respectively). Our findings indicate that six months daily supplementation with the Lab4 probiotic and vitamin C combination reduces the incidence of coughing, absenteeism and antibiotic usage in 3 to 10 year old children.

Download Full-text